Gossamer Bio (FRA:4GB) Debt-to-Equity : 7.82 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Debt-to-Equity?

Gossamer Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €11.26 Mil. Gossamer Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €181.07 Mil. Gossamer Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €24.58 Mil. Gossamer Bio's debt to equity for the quarter that ended in Mar. 2024 was 7.82.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gossamer Bio's Debt-to-Equity or its related term are showing as below:

FRA:4GB' s Debt-to-Equity Range Over the Past 10 Years
Min: -14.12 Med: 0.49 Max: 18.69
Current: 7.82

During the past 8 years, the highest Debt-to-Equity Ratio of Gossamer Bio was 18.69. The lowest was -14.12. And the median was 0.49.

FRA:4GB's Debt-to-Equity is ranked worse than
98.88% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:4GB: 7.82

Gossamer Bio Debt-to-Equity Historical Data

The historical data trend for Gossamer Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Debt-to-Equity Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.57

1.53

18.69

3.39

Gossamer Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-7.82	-3.49	2.06	3.39	7.82

Competitive Comparison of Gossamer Bio's Debt-to-Equity

For the Biotechnology subindustry, Gossamer Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gossamer Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Debt-to-Equity falls into.

Gossamer Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gossamer Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.677	+	181.152)	/	57.559
	=	3.38

Gossamer Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.255	+	181.073)	/	24.584
	=	7.82

Gossamer Bio (FRA:4GB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gossamer Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio (FRA:4GB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GOSS:USA 4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio (FRA:4GB) Headlines

No Headlines